FDA advisory on nevirapine.
The FDA summarized existing warnings against ongoing nevirapine treatment in women with a CD4 count over 250, due to a greatly increased risk of serious liver toxicity. (The warnings do not apply to single-dose nevirapine, which does not cause this problem.)